Skip to main content
Premium Trial:

Request an Annual Quote

Mark Dawson

Cambridge Epigenetix has named Mark Dawson to its scientific advisory board. Dawson is a professor in the Sir Peter MacCallum Department of Oncology and Centre for Cancer Research at the University of Melbourne, where he is the program head of the Translational Haematology Program, group leader of the Cancer Epigenetics Laboratory, and consultant hematologist in the Department of Hematology. His research is focused on epigenetic regulation in normal and malignant hematopoiesis and he is a leading expert on the development of targeted epigenetics-based therapeutics, Cambridge Epigenetix noted.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.